Globally, epilepsy is one of the most common chronic neurological conditions and greatly limits the lives of those affected. Approximately every third patient is refractory to medication and is looking for alternative treatment options. For these patients, EASEE® could be an opportunity to gain better control of their epilepsy and to improve their quality of life. The innovative neurostimulation system, developed by Precisis is currently being tested in the so-called “clinical phase”. At the end of February, the first ever EASEE® implantation was successfully completed.

This press release is only available in german language.

Click here to download press release in german (PDF)

Please contact us directly if you require information in english language. You can find our contact details below:

Precisis AG
Hauptstraße 73
69117 Heidelberg
Tel.: +49 6221 6559300

Gesellschaft für Public Relations mbH
Stefanie Schmidt
Mitteldicker Weg 1 – WEFRA-Haus
63263 Neu-Isenburg – OT Zeppelinheim
Tel.: +49 69 695008-557